According to NICE guidance (NG28), the continuation of GLP-1 receptor agonist therapy in type 2 diabetes should be assessed after six months, with treatment continued only if there is a reduction in HbA1c of at least 11 mmol/mol (1%) and, where applicable, a weight loss of at least 3% of initial body weight
Designed to complement GLP-1 drinks, it fits easily into any diet while supporting overall wellness with a delicious berry flavor
I'm truly grateful for your clinic and I recommend you to everyone!" Heather B
Phase 3 TRIUMPH trial data on long-term discontinuation effects are still emerging as of 2026
For people actively losing weight on semaglutide, a couple of these functions are especially relevant
It sounds a cautionary note for short-term use without a more comprehensive approach to weight management.' Image source: West S, Scragg J, Aveyard P et al., The BMJ 2026 (CC BY 4.0) The Oxford team systematically reviewed 37 studies tracking more than 9,000 adults who stopped taking weight management medicines after being on them for an average of 39 weeks of treatment
